Russian Missile Strike Sparks Fires in Kyiv After Early Morning Air Alert 
Iran Says It Closes Strait of Hormuz After Warning Shot at Vessel 
Trump Slams New York Data Center Ban, Warns AI Investment Could Shift to Other States 
Asian Stocks Rally as Cooling U.S. Inflation Boosts Fed Rate Cut Hopes 
Reuters/Ipsos Poll: Most Americans Expect U.S.-Iran War to Be Prolonged 
Gold Price Holds Near Record High as Cooling U.S. Inflation Offsets Fed Caution 
China Trade Surplus Hits $125.6 Billion as June Exports, Imports Smash Forecasts 
EU to Propose New Rules Limiting Children's Access to Social Media 
Port of Los Angeles Posts Record June Cargo Volume as Importers Rush Ahead of U.S. Tariffs 
Japanese Yen Holds Steady as Intervention Hopes Grow Ahead of U.S. CPI Data 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Senate Weighs Permanent Daylight Saving Time Bill as Support Remains Uncertain 
Trump Tells Congress Iran Hostilities Restarted, Citing New 60-Day War Powers Window 
Israel-Lebanon Talks Resume in Rome as Ceasefire and Troop Withdrawal Remain Elusive 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Asian Stocks Rise as Softer U.S. Inflation Boosts Sentiment Despite Middle East Tensions 
U.S. President Donald Trump announced sweeping new trade tariffs Thursday evening, including a 100% levy on imported pharmaceutical products, marking one of his most aggressive moves to date in reshaping America’s trade policy. The new tariffs, set to take effect October 1, will also include a 25% duty on heavy truck imports, 50% on kitchen and bathroom fittings, and 30% on upholstered furniture.
According to Trump, the pharmaceutical tariffs will apply to all branded or patented products, though companies actively building manufacturing plants in the United States will be exempt. He specified that firms must have already broken ground or begun construction on U.S. facilities to qualify. Trump framed the move as a matter of national security and a necessary step to reduce dependency on foreign drug imports.
The United States imported over $212 billion worth of pharmaceutical products in 2024, government data shows. Trump has long criticized this reliance, arguing that it threatens U.S. security and weakens domestic industries. Earlier this year, he demanded that 17 major drugmakers lower domestic drug prices while raising them abroad to balance profits. In August, Trump warned he could hike tariffs as high as 250%, signaling the seriousness of his push for reshoring production.
The tariff threats have already spurred huge investment pledges from global pharma companies. Roche committed to investing $50 billion, while Novartis announced $23 billion in U.S. facilities. American firms including Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are also ramping up domestic operations to hedge against the new trade policies.
These tariffs extend beyond pharmaceuticals, targeting industries like heavy trucks, fittings, and furniture—sectors Trump says need protection to revive U.S. manufacturing and safeguard jobs. While the full impact of these measures on trade partners remains unclear, they underscore the administration’s continued reliance on tariffs as a core tool in its economic agenda.
